翰思艾泰生物医药科技（武汉）股份有限公司（股票代码：03378，简称“翰思艾泰-B”）于2026年5月6日发布公告，披露在香港联交所场内回购股份事宜。此次回购股份数量为25,900股，占该公司回购前已发行股份总数约0.02%，每股价格介乎30.00港元至31.20港元，支付总金额约79.57万港元。
此次回购完成后，翰思艾泰-B的已发行股份总数维持136,218,830股，其中135,732,730股为流通股份，486,100股为库藏股。公司已于2026年2月12日通过购回授权，可回购股份总数为13,621,883股，截至目前，根据该授权于本交易所或其他交易所已回购486,100股。
公告显示，翰思艾泰-B确认已遵守香港联交所证券上市规则及相关法律规定，并已履行必要的公司内部批准程序。
本公告由翰思艾泰-B董事长兼执行董事张发明签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.